Pfizer Inc. (NYSE: PFE) traded lower today, with shares last seen around $26.59 (down $0.27, or -0.99%) as investors weighed encouraging oncology signals against a tougher near-term setup tied to patent expirations and post-pandemic normalization.
The pullback came even as Pfizer continues to push its growth narrative in cancer therapies. Management has leaned into oncology as a core pillar, and the category has been one of the brighter spots for the company’s revenue mix. Pfizer’s oncology sales grew 8% in 2025 and now represent roughly 27% of total revenue, supported by key products including Xtandi, Lorbrena, the Braftovi–Mektovi combination, and Padcev.
One focus area attracting attention is Pfizer’s BRAFTOVI program. Recent trial updates have been described as positive, reinforcing the broader view that Pfizer’s oncology pipeline can deliver longer-term revenue streams, even if near-term readouts and timelines keep sentiment cautious.
That caution has been amplified by mixed analyst commentary. Barclays initiated coverage on Pfizer with an Underweight rating and set a $25 price target, pointing to upcoming loss-of-exclusivity pressures that begin this year and accelerate through 2028. The firm also highlighted balance-sheet constraints and a near-term focus on deleveraging, with Pfizer’s debt-to-equity ratio cited at 0.67. The implication is that valuation may look attractive, but catalysts could arrive slowly, keeping the stock range-bound until key updates land.
At the same time, Pfizer has continued to show it can still beat expectations on execution. In its most recent quarter, the company reported revenue of $17.6 billion, topping the consensus estimate of $16.6 billion. Adjusted EPS came in at $0.66, above the $0.58 forecast. Even so, the market’s focus remains on the transition away from COVID-era revenue. Pfizer expects COVID revenues to land around $5 billion in 2026, down from roughly $6.7 billion in 2025, as demand for Comirnaty and Paxlovid continues to cool.
Competition is another pressure point. In oncology, Pfizer is going up against AstraZeneca and other large-cap peers that already generate bigger cancer-focused revenue bases. AstraZeneca’s oncology segment accounts for roughly 44% of total revenue, illustrating the scale Pfizer is trying to match as it builds share and advances new therapies.
For investors looking at valuation, Pfizer’s numbers have shifted in a direction that typically attracts value buyers. Pfizer’s P/E ratio declined from 17.48x in Q1 2025 to 13.75x by Q3 2025, while EV/EBITDA rose modestly to 11.36x. On profitability, gross margins improved to 73.39% and operating margin remained healthy at 21.85%, reflecting cost management even as the company invests heavily in R&D and pipeline development.
Income investors also continue to cite Pfizer’s dividend profile as a key support. Pfizer has maintained dividend payments for 56 consecutive years and the dividend yield has been cited near 6.4%, a standout figure among large-cap pharma peers. Still, the sustainability narrative is tied to how efficiently Pfizer can bridge the patent cliff while rebuilding growth through launches and acquisitions.
Pipeline uncertainty remains front and center in near-term trading. Pfizer recently shared positive results from its BREAKWATER trial in colorectal cancer, but the treatment is not yet FDA-approved, leaving investors to price in both potential upside and timing risk. Separately, Pfizer is seeking FDA approval for its hemophilia drug HYMPAVZI for younger patients, with a decision expected in Q2 2026.
Beyond core pharma, Pfizer is also positioned in adjacent consumer-health style categories tied to nicotine and tobacco alternatives. The nicotine gum market is projected to reach $2.55 billion by 2030, while tobacco alternatives are projected to reach $4.25 billion by 2030. These markets are not expected to move the needle like oncology, but they can provide incremental diversification and steadier demand cycles.
Another datapoint investors have watched is insider activity. Pfizer insiders reported 10 transactions totaling $677,546.71, primarily 9 equity awards and 1 tax payment, which does not read as an aggressive directional signal.
Outlook: Pfizer’s near-term setup remains constrained by the 2026–2028 patent cycle and post-COVID normalization, but the long-term argument rests on oncology execution, pipeline approvals, and the ability of newer products to drive sustained, non-COVID growth.
You may like to read:
- Cloudflare Outage Crashes Bet365, Sky Bet and Uber Eats as Thousands Locked Out Worldwide
- Apple Stock (AAPL) Jumps as 267 vs 1.47M Reporting Gap Sparks Legal Heat
For additional context on analyst ratings, see the full coverage initiation details via Investing.com’s analyst report.
